Site Search
Professionals 96 results
Capabilities 42 results
Industry
Winston has been a major player in the life sciences industry for decades. We represent market-leading clients across this broad sector, including companies involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a unique understanding of the industry and perspective to our representations.
Practice Area
As society and business become even more digitalized, technology and intellectual property (IP) have become key focal points for businesses. Our Technology Antitrust Group combines the cross-practice and cross-office experience of our lawyers to assist clients in successfully navigating the dynamic convergence of technology, antitrust, and IP law. We understand the challenges presented by the ever-changing digital landscape and are committed to providing our clients with tailored solutions to address their specific needs.
Practice Area
Experience 105 results
Experience
|December 3, 2025
US Tiger Securities Announced IPO
Winston & Strawn LLP is serving as U.S. securities counsel to US Tiger Securities, Inc., a full-service broker/dealer, in connection with the $10,000,000 initial public offering of SMJ International Holdings Inc., a Singapore-based premium flooring specialist. The Company priced 2,500,000 Class A ordinary shares at US$4.00 per share. The Class A ordinary shares are expected to begin trading on the NYSE American under the ticker symbol “SMJF” on December 4, 2025.
Experience
|October 1, 2025
AA Mission Acquisition Corp. II - Initial Public Offering
Winston & Strawn LLP represented AA Mission Acquisition Corp. II, a blank check company, in the recent closing of its $100 million Initial Public Offering (IPO). The offering consisted of 10,000,000 units priced at $10.00 per unit, before deducting underwriting discounts and estimated offering expenses. The units began trading on the New York Stock Exchange (NYSE) under the ticker symbol “YCY.U” on October 1, 2025.
Experience
|July 30, 2025
Represent Norman W. Fries, Inc. d/b/a Claxton Poultry Farms in a series of 15+ antitrust class actions consolidated in the Northern District of Illinois and brought by plaintiffs who allege that Claxton and the nation’s other largest poultry producers conspired to fix the price of broiler chickens in a scheme from 2008 to 2016 that raised the price for broiler chickens by artificially reducing supply.
Insights & News 724 results
Seminar/CLE
|January 20, 2026
Winston & Strawn and RSM US LLP are co-hosting the annual NYC SBIC Fund Conference on Tuesday, January 20, 2026.General and limited partners, chief financial officers, and controllers of small business investment company (SBIC) funds are invited to a half-day seminar covering various topics related to SBIC fund operations, including:
In the Media
|January 7, 2026
|1 Min Read
Kevin Brophy Shares Market Outlook on Natural Gas and Oil in Hart Energy
Kevin Brophy, co-chair of Winston & Strawn’s Energy & Infrastructure Industry Group, was featured in Hart Energy discussing the diverging outlooks for natural gas and oil markets and the implications for investment, capital allocation, and deal activity heading into 2026.
Competition Corner
|December 23, 2025
|4 Min Read
New York recently expanded its algorithmic pricing laws, now requiring retailers to disclose when prices are set with algorithmic software based on consumers’ personal data.The so-called practice of surveillance pricing entails adjusting prices charged for goods and services according to monitored personal data.
Other Results 33 results
Site Content
What Is the Price Range in an IPO?
The price range is a proposed price per share range for the IPO within which investors can bid for shares and which is often printed on the cover page of a preliminary prospectus. The price range has a minimum price, known as the floor price, and a maximum price, known as the cap price.
Site Content
Congress enacted the Biologics Price Competition and Innovation Act (BPCIA) to provide an abbreviated pathway for biosimilars to gain FDA approval through submission of an abbreviated Biologics License Application (aBLA).
Site Content
Dilution refers to the reduction in an existing shareholder’s ownership percentage of a company when the company issues additional shares. Dilution in an IPO results from a disparity between the public offering price in an IPO and the effective cash cost to persons who acquired shares prior to the IPO. Dilution is disclosed in the registration statement in a dilution table.